Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAITILS: Hepatic Arterial Infusion of TILs in Melanoma
NCT04812470Phase 1Completed
- Sponsor
- Region Västra Götaland
- Start
- Feb 2023
- Primary completion
- May 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MDA-TIL in Uveal melanoma (UM) and cutaneous melanoma (CM), sponsored by Region Västra Götaland. Primary endpoint: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) at 5 years. Started Feb 2023; status: completed.
02
Drugs
MDA-TIL
03
Conditions
Uveal melanoma (UM)cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT04812470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04812470.